NCT01002885|Completed
Follicle Stimulating Hormone (FSH) Receptor Polymorphisms in In-Vitro Fertilization Cycles.
The Use of FSH Receptor Polymorphisms To Improve Pregnancy Rates In In-Vitro Fertilization
Loading search results
The Use of FSH Receptor Polymorphisms To Improve Pregnancy Rates In In-Vitro Fertilization
Sponsor study identifier
observational
75
1 country
2
Study Start
July 2009
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
March 2013
Actual (reported)Study Completion
May 2013
Actual (reported)This study is being done to identify if certain sequences (patterns) of key genes (called polymorphisms) may predict a response to fertility medications. The investigators will also determine if the individual response to fertility medications affects pregnancy rates in in-vitro fertilization.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
May 2013
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
July 2009
Date type not reportedThis date has not been verified as actual or estimated.
October 26, 2009
Actual (reported)October 28, 2009
Actual (reported)March 2013
Actual (reported)May 2013
Actual (reported)The primary outcome measure is to evaluate the frequency of FSH receptor polymorphisms in our population.
The investigators are looking to quantify how often certain FSH receptor Polymorphisms occur in the population and cetain racial groups. We will be looking at patient's race along with the laboratory results.
3 years
The secondary outcome is to further clarify the variation in response to FSH due to FSH receptor polymorphisms using the protocols largely used in the United States, including our center.
3 years
Patients undergoing in-vitro fertilization will be recruited. Inclusion criteria will limit the patient population to those patients most likely to have normal ovarian function since age or disease related ovarian dysfunction will confound interpretation of our results.
University Reproductive Associates
Hasbrouck Heights, New Jersey, 07604, United States
University Reproductive Associates
Hoboken, New Jersey, 07030, United States
2 EDTA containing lavender topped tubes will be collected before, during or within 3 months after an IVF cycle. Genomic DNA will be extracted and saved for genotyping.
Aimee Seungdamrong, MD
University Reproductive Associates
75 participants (actual enrollment reported by the registry).
First Submitted
October 26, 2009
First Posted
October 28, 2009
Study Start
July 2009
Date type not reportedThis date has not been verified as actual or estimated.
Vaginal Progesterone Versus Progesterone in Oil in Donor Egg Recipient In Vitro Fertilization Cycles Utilizing Vitrified Donor Eggs
Contact the study team to confirm eligibility.
Primary Completion
March 2013
Actual (reported)Study Completion
May 2013
Actual (reported)Last Updated
December 10, 2013
Record last verified: 2013-12
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: